神経芽腫治療の変遷と問題点(I 主要疾患の遠隔成績, 25周年記念シンポジウム論文)

概要

論文の詳細を見る
Ninety-nine patients with neuroblastoma have been treated in our department. Overall 5-year survival rates were 100% in stage I, 60% in stage III, 12.5% in stage IV and 70% in stage IVS. The changes in therapeutic methods and the results were evaluated and the subsequent problems were debated. Pre and post-operatfve adjuvant chemotherapy of advanced neuroblatoma has been changed from mild to agressive one (high dose cyclophosphamide treatment) and delayed primary operation was induced in 1978. Synchronization chemotherapy and second look operation were instituted in 1980. Sublethal dose chemotherapy with autologous bone marrow transplantation was performed in 1985. The survival rate of neuroblastoma was remarkably improved after 1978. However the unusual case of late recurrence 10 years after complete remission was also experienced. Therapeutic result of neurolatoma is expected to be improved gradually because of the development of treatment and the introduction of mass screening. To achieve the goal,further continued efforts have to be made in every respect.
特定非営利活動法人日本小児外科学会の論文
1989-10-20